According to a study published in Diabetes, Obesity and Metabolism that assessed the occurrence of gastrointestinal (GI) adverse events (AEs) with a 2.4-milligram weekly dose, 29.7% of participants reported diarrhea and 24.2% had constipation
H) where the injection will be given Figure G: top of the arm Step 15
Interestingly, regulation of SDF-1 is maintained by signaling through another DPP4 substrate, G-CSF
Unused pens should be kept refrigerated (2C8C)
Zepbound (Tirzepatide Injection) For those considering tirzepatide, Zepbound stands as the injectable option, proven effective in weight management through substantial trial results
The chemiluminescence kit was obtained from Vazyme Biotech, Nanjing, China